Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,669,557 papers from all fields of science
Search
Sign In
Create Free Account
SAR260301
Known as:
PI3K-beta Inhibitor SAR260301
, SAR 260301
, SAR-260301
Expand
An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Concomitant Inhibition of PI 3 K b andBRAForMEK in PTEN-De fi cient / BRAF-Mutant Melanoma Treatment : Preclinical Assessment of SAR 260301 Oral PI 3 K b-Selective Inhibitor H el
ene Bonnevaux
,
O. Lemaitre
,
+7 authors
A. Virone-Oddos
2016
Corpus ID: 39562457
Class IA PI3K pathway activation resulting from PTEN deficiency has been associated with lack of sensitivity of melanoma to BRAF…
Expand
2013
2013
Abstract 3258: Discovery and characterization of SAR260301, a novel PI3Kβ-selective inhibitor in clinical development for the treatment of PTEN-deficient tumors .
A. Virone-Oddos
,
Hélène Bonnevaux
,
+16 authors
C. García-echeverría
2013
Corpus ID: 73249340
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC The PI3K/mTOR pathway is involved in promoting tumor…
Expand